Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells
© Gola et al.; lincensee BioMed Central Ltd. 2013
Received: 12 June 2012
Accepted: 22 January 2013
Published: 29 January 2013
Posttraumatic stress disorder (PTSD) is associated with an enhanced risk for cardiovascular and other inflammatory diseases. Chronic low-level inflammation has been suggested as a potential mechanism linking these conditions.
We investigated plasma cytokine levels as well as spontaneous and lipopolysaccharide (LPS)-stimulated cytokine production by peripheral blood mononuclear cells (PBMCs) in a group of 35 severely traumatized PTSD patients compared to 25 healthy controls.
Spontaneous production of interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α by isolated PBMCs was significantly higher in the PTSD compared to the control group and even correlated with PTSD symptom severity within the PTSD group. In contrast, circulating plasma levels of pro- and anti-inflammatory cytokines such as IL-6, IL-8, IL-10, TNF-α, or monocyte chemotactic protein (MCP)-1 were not significantly altered in PTSD patients compared to healthy controls.
Our findings indicate that PBMCs of PTSD patients are already pre-activated in vivo, providing further evidence for low-grade inflammation in PTSD. This might possibly represent one psychobiological pathway from PTSD to poor physical health.
KeywordsPosttraumatic stress disorder Immune system Cytokines Pro-inflammatory cytokines Traumatic stress Inflammation
Repeated exposure to traumatic events such as rape, combat or natural disasters has dramatic effects on mental health [1–3]. Frequent symptoms in the aftermath of such events include repetitive intrusive recollections of the trauma, persistent avoidance of trauma reminders, emotional numbing and hyperarousal – the core symptoms of posttraumatic stress disorder PTSD .
In addition to psychiatric morbidity, numerous studies have shown that traumatic stress and especially PTSD are associated with poor self-reported physical health, increased utilization of medical services, and an elevated risk for multiple comorbid medical disorders such as respiratory, gastrointestinal, musculoskeletal, inflammatory and autoimmune diseases [5–7]. In particular, it has been found that cardiovascular disease and its risk factors are more prevalent among individuals with PTSD [5, 6, 8], with two recent studies even demonstrating a prospective relationship between PTSD symptoms and coronary heart disease  or PTSD and cardiovascular mortality, respectively .
Besides traditional behavioral cardiovascular risk factors such as smoking, alcohol abuse or low physical activity , chronic low-level inflammation has been discussed as a potential mechanism linking cardiovascular disease to PTSD . This argumentation is supported by epidemiological and clinical studies demonstrating a strong and consistent relationship between markers of inflammation and risk of future cardiovascular events [13, 14].
However, studies investigating pro-inflammatory markers in PTSD patients have yielded mixed results. Some studies reported higher levels of IL-1β [15, 16], IL-6 , and TNF-α  in the plasma or elevated levels of IL-6 in the cerebrospinal fluid  of PTSD patients compared to control subjects. Furthermore, Spitzer et al.  found that, in a sample of 3049 adults, PTSD positive participants had significantly higher odds for elevated levels of C-reactive protein (CRP) than those without PTSD. In contrast, other studies did not find significant group differences with respect to circulating levels of IL-1β , IL-6 [12, 20], and CRP  or even reported lower levels of CRP  and IL-8  in PTSD patients.
Likewise, ambiguous results have been obtained by studies investigating the production of pro-inflammatory cytokines in whole blood following ex vivo stimulation with lipopolysaccharide (LPS) and/or phytohemagglutinin (PHA). Whereas some studies reported higher LPS-stimulated IL-6 production  or increased LPS/PHA-induced production of IL-6 and TNF-α  in individuals with PTSD, other studies showed no group differences with respect to PHA-induced interferon (IFN)-γ  or LPS-induced TNF-α production . One study by de Kloet et al.  even reported decreased TNF-α production in LPS-stimulated whole blood of PTSD patients compared to controls.
These inconsistent findings might partly be explained by variations in sample characteristics, such as differences with respect to the type of traumata experienced (e.g. childhood vs. adulthood trauma), time elapsed since the traumata (e.g. populations studied shortly after traumatic experiences or during ongoing threat vs. patients with chronic symptoms), comorbidities, and differences with respect to PTSD symptom severity (mild symptoms after a single trauma in comparison to severe symptoms after experiencing multiple traumata), as well as varying sample sizes. In particular studies investigating plasma cytokine levels consisted mostly of small patient groups, making the results error-prone.
Here we investigated plasma levels of pro- and anti-inflammatory cytokines in a well-defined group of 35 severely affected PTSD patients with war and torture experiences mainly experienced during late adolescence and adulthood and a chronic disease pattern, compared to 25 healthy ethnically matched control subjects. For a subsample of 16 PTSD patients and 18 control subjects, we additionally analyzed 1) LPS-stimulated production of IL-1β, IL-6 and TNF-α by peripheral blood mononuclear cells (PBMCs), as well as 2.) spontaneous cytokine production by these cells, as this has not been reported previously.
Sociodemographic and clinical characteristics of PTSD patients and controls
(n = 35)
(n = 25)
32.6 ± 9.1
29.1 ± 9.7
Region of Origin (%)
Psychotropic medication (%)
Comorbid depression (%)
Number of traumatic event typesa
War or torture events
10.8 ± 5.4
2.3 ± 5.0
6.9 ± 2.1
3.4 ± 2.0
80.0 ± 17.5
5.4 ± 11.2
26.1 ± 8.2
4.1 ± 5.6
28.7 ± 12.4
5.5 ± 8.5
Exclusion criteria for the study were intake of glucocorticoids or acute (1 PTSD patient and 2 controls) and chronic (1 PTSD patient and 3 controls) somatic illnesses. In addition, control subjects were excluded if they met the criteria for any mental disorder according to DSM-IV (n = 4), or reported intake of psychotropic medication (n = 2). PTSD patients were excluded if they met the criteria for comorbid alcohol or substance abuse and dependence (n = 3) or a current or past history of a psychosis (n = 1) according to DSM-IV. Furthermore, participants were screened for possible HIV and hepatitis A, B and C infections. All samples were negative for HIV or hepatitis C. Subjects classified with acute or chronic hepatitis A or B (3 PTSD patients and 3 controls) were excluded from the study, reducing the initially enrolled sample of 44 individuals with PTSD and 39 controls to 35 PTSD patients and 25 control participants.
Sociodemographic and clinical characteristics of the subgroup of PTSD patients and control subjects for which we analyzed cytokine production by PBMCs
(n = 16)
(n = 18)
36.1 ± 9.5
26.7 ± 7.4
Region of Origin (%)
Psychotropic medication (%)
Comorbid depression (%)
Number of traumatic event typesa
War or torture events
11.0 ± 5.8
1.8 ± 3.9
7.2 ± 1.7
3.3 ± 1.9
82.5 ± 16.5
7.0 ± 12.8
25.2 ± 8.1
4.6 ± 6.3
28.4 ± 13.8
4.9 ± 8.2
All participants underwent an extensive standardized clinical interview administered by experienced clinical psychologists and trained translators, starting always at 10:00 a.m.: Upon arrival at the outpatient clinic, procedures were explained to the participants and written informed consent was obtained. Subsequently, blood (t1) for white blood cell (WBC) differential counts, plasma cytokines, and PBMC isolation was drawn. Afterwards, sociodemographic information as well as medical information was acquired. Somatic symptoms were assessed using a shortened version of Screening for Somatoform Symptoms 7 SOMS-7, . During the second part of the interview, participants were interviewed in a standardized manner about their individual traumatic experiences using the event checklist of the CAPS  and the vivo checklist of war, detention and torture events, which assesses common traumatic experiences in conflict regions and during torture. Subsequently, PTSD symptom frequency and severity were assessed with the CAPS . Finally, the Mini International Neuropsychiatric Interview M.I.N.I.,  was applied to screen for potential comorbid mental disorders. In addition, depressive symptoms were assessed with the Hamilton Depression Rating Scale HAM-D, . One week after the standardized clinical interview the participants were invited for a second time. Again, blood samples for plasma cytokines were collected at 10:00 am (t2), to test for the stability of basal (t1) cytokine levels.
All procedures were approved by the Ethics Committee of the University of Konstanz and were carried out in accordance with the Declaration of Helsinki 2008.
WBC differential count
Absolute numbers of leukocytes, lymphocytes, neutrophils, monocytes, eosinophils, and basophils were obtained using an automated hematology analyzer (XT-2000i, Sysmex, Horgen, Switzerland).
Peripheral blood mononuclear cells (PBMCs) were isolated from citrated blood by density gradient centrifugation using commercially available cell preparation tubes (Vacutainer® CPT™ Cell Preparation Tube, BD Biosciences, Franklin Lakes, NY, USA) according to the manufacturer’s instructions. Freshly isolated PBMCs (2 × 105) were suspended in 200 μl RPMI 1640 containing 10% fetal bovine serum and were cultured for 24 h in 96-well flat-bottom culture plates in presence or absence of 1 μg/ml lipopolysaccharide (LPS) from Salmonella abortus equi (Sigma-Aldrich, Taufkirchen, Germany).
Cytokine levels in plasma and culture supernatants were quantified using multiplex bead-based assays (Bio-Plex Cytokine Assays, Bio-Rad Laboratories, Hercules, CA, USA). Samples were prepared according to the manufacturer’s instructions and were analyzed in triplicate on a dual-laser flow cytometer equipped with high throughput sampler (LSR II, BD Immunocytometry Systems, San Jose, CA, USA). Absolute cytokine levels were calculated based on the mean fluorescence intensity of cytokine standards. Detection limits of the assays, defined as the mean of background value plus 3 SD, were 0.07 pg/ml (IL-6), 0.75 pg/ml (IL-8), 0.14 pg/ml (IL-10), 0.24 pg/ml (TNF-α), and 0.38 pg/ml (MCP-1), respectively.
Data analysis was performed using R 2.15.2 . Group comparisons with respect to sociodemographic and clinical variables were performed using chi-square tests for categorical data and t-tests for continuous data. Basal plasma and LPS-stimulated cytokine levels were analyzed using ANOVAs with group (PTSD patients vs. controls) as independent variable. Since some of the immunological variables did not met requirements for parametric testing (normality of residuals), statistical significance for the immune measures was assessed by nonparametric permutation tests. In each case, the full model and a reduced model omitting the factor(s) of interest were fitted and the statistic of interest (usually an F statistic) was calculated. Next, residuals under the reduced model were randomly permuted 10,000 times. In each case, the randomly permuted residuals were added back to the (non-permuted) fitted values under the reduced model. The resulting randomized dependent values were then again used in fitting full and reduced models, yielding a “permutation” statistic. The p values reported below are given by the position of the original statistic in the empirical distribution of the permutation statistic [31, 32]. In each case, we also investigated gender as well as smoking status as a covariate. We also wanted to control for the age difference between groups. However, as both groups differed significantly in age, the preconditions for calculating and interpreting an Analysis of Covariance were not fulfilled [33, 34]. In order to nevertheless understand our data better, we calculated Spearman correlations between age and dependent variables separately for the PTSD and control group.
Reported p values represent exact p values. In addition, we report p values corrected for multiple comparisons with Holm’s stepwise procedure , applied first for the five cytokines measured in plasma and then for the three cytokines produced by PBMCs measured in presence or absence of LPS. Correlations were computed using Spearman’s rank correlation coefficient.
Basal plasma cytokine levels
Absolute numbers (cells/μl) of leukocyte subpopulations and plasma cytokine levels (pg/ml) in PTSD patients versus healthy controls
Cytokine production by PBMCs
Correlations with age
Spearman correlations between age on the one hand and plasma IL-6, IL-8, IL-10, TNF-α and MCP-1 at t1 as well as unstimulated and LPS-induced IL-1β, IL-6 and TNF-α production by PBMCs, in each case separately for PTSD patients and control participants, were calculated. None of the correlations were significant.
In the present study we investigated plasma levels of IL-6, IL-8, IL-10, TNF-α and MCP-1 as well as spontaneous and LPS-stimulated production of IL-1β, IL-6 and TNF-α by PBMCs from a group of severely affected PTSD patients compared to healthy control subjects.
While basal plasma concentrations of pro- and anti-inflammatory cytokines did not differ significantly in PTSD patients and controls, we found evidence for a heightened inflammatory state in PTSD patients when analyzing spontaneous ex vivo cytokine production. Concentrations of IL-1β, IL-6, and TNF-α in supernatants of unstimulated PBMCs were significantly higher in the PTSD compared to the control group. In addition, correlation analyses within the PTSD group revealed that levels of IL-6 and TNF-α were significantly related to the severity of PTSD symptoms as assessed with the CAPS; IL-1β was also positively associated, but significance was only at the level of a trend. The group differences reported above were not ascribable to differences in blood leukocyte distribution since lymphocyte and monocyte counts were comparable in both groups. Following the introduction of smoking as covariate to the model, the finding on TNF-α was reduced to a trend. The finding of an increased spontaneous production of pro-inflammatory cytokines in the PTSD patients group suggests that PBMCs of PTSD patients are already pre-activated in vivo. Furthermore, as in previous studies [22, 23], LPS-stimulated PBMCs from PTSD patients exhibited significantly higher IL-6 secretion compared to PBMCs from control subjects. However, when calculating the difference between LPS-stimulated and non-stimulated cytokine production to evaluate the net effect of LPS stimulation, no group differences were found, suggesting that the effect reported above mainly results from the enhanced spontaneous IL-6 secretion by PBMCs of PTSD patients. Our finding of a heightened spontaneous production of pro-inflammatory cytokines in the PTSD patient group is in agreement with reports that parameters normally suppressing inflammation are reduced in PTSD patients. For example, studies have reported lower cortisol levels  and a lower percentage of regulatory T cells  in those with PTSD, which are both crucial players in controlling inflammation thereby limiting immunopathological side effects of inflammatory processes [38, 39]. Consequently our results provide further evidence for a link between PTSD and low-grade inflammation, possibly representing one psychobiological pathway from PTSD to inflammatory diseases such as arteriosclerosis and its clinical manifestations, e.g., myocardial infarction, stroke, and peripheral vascular disease, often observed in patients with PTSD [5, 8]. Whereas arteriosclerosis has been formerly considered a simple lipid storage disease, current evidence supports a fundamental role for inflammation in mediating all stages of this disease. Inflammatory processes not only promote early atherogenesis and the progression of lesions, but also contribute decisively to precipitating acute thrombotic complications of atheroma. In addition, clinical studies affirm a correlation of circulating markers of inflammation with propensity to develop ischemic events and with prognosis after acute coronary syndromes [13, 14].
In conclusion, repeated exposure to traumatic events over the lifetime seems to induce long-lasting changes in the regulation of inflammatory processes that constitute a form of biological memory of the stressor and might lead in the long run due to self-perpetuating processes to the development of various physical diseases. However, the interpretation of our results is faced with several limitations of our study: 1) Groups differed significantly with respect to age. Unfortunately, correcting for age is only possible if groups do not differ in this variable see [33, 34]. But as a) spontaneous production of IL-1β, IL-6, and TNF-α was not significantly correlated with age, neither for controls nor for PTSD subjects and b) it was positively related to PTSD symptom severity within the PTSD group, older age in the PTSD group should not have accounted for the effects reported above 2) One third of the PTSD patients took psychotropic medication. 3) We did not control for the confounding effects of physical activity on the immune outcomes. Moreover, as earlier studies suggest, a heightened inflammatory state does not seem to hold true for all studied populations of PTSD patients [20, 21, 24]. Future studies should therefore investigate whether a heightened inflammatory profile is associated with a specific characteristic of PTSD, e.g., whether it can only be found in PTSD patients with chronic and severe symptoms or is modulated by the type of trauma experienced. Eventually, such findings could be the basis for the development of new trauma treatment approaches, paying more attention to the potential for improving physical, in addition to mental health.
Below detection limit
Clinician Administered PTSD Scale
Hamilton Depression Rating Scale
Monocyte chemotactic protein
Mini International Neuropsychiatric Interview
Peripheral blood mononuclear cells
Posttraumatic stress disorder
Screening for Somatoform Symptoms-7
Tumor necrosis factor
White blood cell.
We thank Dr. Claudia Catani, Dr. Maggie Schauer, Dr. Martina Ruf and Prof. Dr. Frank Neuner for clinical supervision and treatment of patients as well as Heike Riedke and Christiane Wolf for technical assistance. This research was conducted at the University of Konstanz. Hannah Gola and Iris-Tatjana Kolassa are now at the University of Ulm.
This study was funded by the German Research Foundation (DFG) FOR751 and the European Refugee Fund. The DFG and the European Refugee Fund had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
- Kolassa IT, Ertl V, Eckart C, Kolassa S, Onyut LP, Elbert T: The probability of spontaneous remission from PTSD depends on the number of traumatic event types experienced. Psychological Trauma: Theory, Research, Practice, and Policy. 2010, 2: 169-174.View Article
- Neuner F, Schauer M, Karunakara U, Klaschik C, Robert C, Elbert T: Psychological trauma and evidence for enhanced vulnerability for posttraumatic stress disorder through previous trauma among West Nile refugees. BMC Psychiatry. 2004, 4: 34-10.1186/1471-244X-4-34.PubMed CentralView ArticlePubMed
- Kolassa IT, Kolassa S, Ertl V, Papassotiropoulos A, De Quervain DJ: The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-o-methyltransferase Val(158)Met polymorphism. Biol Psychiatry. 2010, 67: 304-308. 10.1016/j.biopsych.2009.10.009.View ArticlePubMed
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 1994, Washington DC: American Psychiatric Association
- Schnurr PP, Jankowski MK: Physical health and post-traumatic stress disorder: review and synthesis. Semin Clin Neuropsychiatry. 1999, 4: 295-304.PubMed
- Boscarino JA: Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. Ann N Y Acad Sci. 2004, 1032: 141-153. 10.1196/annals.1314.011.View ArticlePubMed
- Walker EA, Katon W, Russo J, Ciechanowski P, Newman E, Wagner AW: Health care costs associated with posttraumatic stress disorder symptoms in women. Arch Gen Psychiatry. 2003, 60: 369-374. 10.1001/archpsyc.60.4.369.View ArticlePubMed
- Kubzansky LD, Koenen KC: Is post-traumatic stress disorder related to development of heart disease?. Future Cardiol. 2007, 3: 153-156. 10.2217/147966184.108.40.206.View ArticlePubMed
- Kubzansky LD, Koenen KC, Spiro A, Vokonas PS, Sparrow D: Prospective study of posttraumatic stress disorder symptoms and coronary heart disease in the normative aging study. Arch Gen Psychiatry. 2007, 64: 109-116. 10.1001/archpsyc.64.1.109.View ArticlePubMed
- Boscarino JA: A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. Psychosom Med. 2008, 70: 668-676. 10.1097/PSY.0b013e31817bccaf.PubMed CentralView ArticlePubMed
- Schnurr PP, Green BL: Trauma and health: physical health consequences of exposure to extreme stress. 2004, Washington, DC: American Psychological AssociationView Article
- von Kanel R, Hepp U, Kraemer B, Traber R, Keel M, Mica L, Schnyder U: Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res. 2007, 41: 744-752. 10.1016/j.jpsychires.2006.06.009.View ArticlePubMed
- Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation. 2004, 109: II2-10.View ArticlePubMed
- Libby P: Inflammation in atherosclerosis. Nature. 2002, 420: 868-874. 10.1038/nature01323.View ArticlePubMed
- Tucker P, Ruwe WD, Masters B, Parker DE, Hossain A, Trautman RP, Wyatt DB: Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol Psychiatry. 2004, 56: 121-128. 10.1016/j.biopsych.2004.03.009.View ArticlePubMed
- Spivak B, Shohat B, Mester R, Avraham S, Gil-Ad I, Bleich A, Valevski A, Weizman A: Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. Biol Psychiatry. 1997, 42: 345-348. 10.1016/S0006-3223(96)00375-7.View ArticlePubMed
- Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, De Jongh R, Bosmans E: Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry. 1999, 45: 833-839. 10.1016/S0006-3223(98)00131-0.View ArticlePubMed
- Baker DG, Ekhator NN, Kasckow JW, Hill KK, Zoumakis E, Dashevsky BA, Chrousos GP, Geracioti TD: Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation. 2001, 9: 209-217. 10.1159/000049028.View ArticlePubMed
- Spitzer C, Barnow S, Volzke H, Wallaschofski H, John U, Freyberger HJ, Lowe B, Grabe HJ: Association of posttraumatic stress disorder with low-grade elevation of C-reactive protein: evidence from the general population. J Psychiatr Res. 2010, 44: 15-21. 10.1016/j.jpsychires.2009.06.002.View ArticlePubMed
- Song Y, Zhou D, Guan Z, Wang X: Disturbance of serum interleukin-2 and interleukin-8 levels in posttraumatic and non-posttraumatic stress disorder earthquake survivors in northern China. Neuroimmunomodulation. 2007, 14: 248-254. 10.1159/000112050.View ArticlePubMed
- Sondergaard HP, Hansson LO, Theorell T: The inflammatory markers C-reactive protein and serum amyloid A in refugees with and without posttraumatic stress disorder. Clin Chim Acta. 2004, 342: 93-98. 10.1016/j.cccn.2003.12.019.View ArticlePubMed
- Rohleder N, Joksimovic L, Wolf JM, Kirschbaum C: Hypocortisolism and increased glucocorticoid sensitivity of pro-Inflammatory cytokine production in Bosnian war refugees with posttraumatic stress disorder. Biol Psychiatry. 2004, 55: 745-751. 10.1016/j.biopsych.2003.11.018.View ArticlePubMed
- Gill J, Vythilingam M, Page GG: Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J Trauma Stress. 2008, 21: 530-539. 10.1002/jts.20372.PubMed CentralView ArticlePubMed
- de Kloet CS, Vermetten E, Bikker A, Meulman E, Geuze E, Kavelaars A, Westenberg HG, Heijnen CJ: Leukocyte glucocorticoid receptor expression and immunoregulation in veterans with and without post-traumatic stress disorder. Mol Psychiatry. 2007, 12: 443-453.PubMed
- Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a clinician-administered PTSD scale. J Trauma Stress. 1995, 8: 75-90. 10.1002/jts.2490080106.View ArticlePubMed
- Rief W, Hiller W: A new approach to the assessment of the treatment effects of somatoform disorders. Psychosomatics. 2003, 44: 492-498. 10.1176/appi.psy.44.6.492.View ArticlePubMed
- Schauer M, Neuner F, Elbert T: Narrative Exposure Therapy. 2011, Göttingen, Germany: Hogrefe & Huber, 2nd
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998, 59 (Suppl 20): 22-33. quiz 34–57PubMed
- Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23: 56-62. 10.1136/jnnp.23.1.56.PubMed CentralView ArticlePubMed
- R Development Core Team: R: A language and environment for statistical computing. 2010, Vienna, Austria: R Foundation for Statistical Computing
- Good PI: Permutation, Parametric and Bootstrap Tests of Hypotheses. 2005, New York, NY: Springer, 3rd
- Anderson MJ, Legendre P: An empirical comparison of permutation methods for tests of partial regression coefficients in a linear model. J Stat Comput Simul. 1999, 62: 271-303. 10.1080/00949659908811936.View Article
- Miller GA, Chapman JP: Misunderstanding analysis of covariance. J Abnorm Psychol. 2001, 110: 40-48.View ArticlePubMed
- Lord FM: A paradox in the interpretation of group comparisons. Psychol Bull. 1967, 68: 304-305.View ArticlePubMed
- Holm S: A simple sequentially rejective multiple test procedur. Scand J Stat. 1979, 6: 65-70.
- Yehuda R: Biology of posttraumatic stress disorder. J Clin Psychiatry. 2001, 62 (Suppl 17): 41-46.PubMed
- Sommershof A, Aichinger H, Engler H, Adenauer H, Catani C, Boneberg EM, Elbert T, Groettrup M, Kolassa IT: Substantial reduction of naive and regulatory T cells following traumatic stress. Brain Behav Immun. 2009, 23: 1117-1124. 10.1016/j.bbi.2009.07.003.View ArticlePubMed
- Mills KH: Regulatory T cells: friend or foe in immunity to infection?. Nat Rev Immunol. 2004, 4: 841-855. 10.1038/nri1485.View ArticlePubMed
- Besedovsky HO, del Rey A: Regulating inflammation by glucocorticoids. Nat Immunol. 2006, 7: 537-View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/13/40/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.